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Background. Since the mid-1990s, effective antiretroviral therapy (ART) regimens have improved in potency,
tolerability, ease of use, and class diversity. We sought to examine trends in treatment initiation and resulting
human immunodeficiency virus (HIV) virologic suppression in North America between 2001 and 2009, and de-
mographic and geographic disparities in these outcomes.
Methods. We analyzed data on HIV-infected individuals newly clinically eligible for ART (ie, first reported
CD4+ count <350 cells/µL or AIDS-defining illness, based on treatment guidelines during the study period) from
17 North American AIDS Cohort Collaboration on Research and Design cohorts. Outcomes included timely ART
initiation (within 6 months of eligibility) and virologic suppression (≤500 copies/mL, within 1 year). We exam-
ined time trends and considered differences by geographic location, age, sex, transmission risk, race/ethnicity,
CD4+ count, and viral load, and documented psychosocial barriers to ART initiation, including non–injection
drug abuse, alcohol abuse, and mental illness.
Results. Among 10 692 HIV-infected individuals, the cumulative incidence of 6-month ART initiation in-
creased from 51% in 2001 to 72% in 2009 (Ptrend < .001). The cumulative incidence of 1-year virologic suppression
increased from 55% to 81%, and among ART initiators, from 84% to 93% (both Ptrend < .001). A greater number
of psychosocial barriers were associated with decreased ART initiation, but not virologic suppression once ART
was initiated. We found significant heterogeneity by state or province of residence (P < .001).
Conclusions. In the last decade, timely ART initiation and virologic suppression have greatly improved in
North America concurrent with the development of better-tolerated and more potent regimens, but significant
barriers to treatment uptake remain, both at the individual level and systemwide.
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Since the mid-1990s, effective antiretroviral therapy (ART)
regimens to treat human immunodeficiency virus (HIV) infec-
tion have improved in potency, tolerability, ease of use, and
antiretroviral class diversity [1]. These have been linked to im-
provements in treatment adherence [2, 3] and clinical out-
comes [4]. However, not all who are clinically eligible start
treatment, a scenario sometimes associated with substance
abuse and suboptimal insurance coverage, among other
factors [5].
Monitoring trends in the successful initiation of ART is im-
portant, especially as population-based interventions such as
expanded “test-and-treat” initiatives are introduced [6, 7] and
as treatment guidelines recommend starting therapy at higher
CD4+ counts [8, 9]. Collectively, these changes increase the
identification of previously undiagnosed individuals and, con-
sequently, the pool of persons newly eligible for treatment.
Owing to their size and heterogeneity, collaborative observa-
tional studies are particularly useful to monitor trends [10].
They can help identify disparities among subpopulations, in-
cluding those defined by geography, which may be informative
as many health policies are instituted at the state or province
level. Reducing HIV-related health disparities in vulnerable
populations is a priority of both the US National HIV/AIDS
Strategy and the Federal Initiative to Address HIV/AIDS in
Canada [11, 12].
We examined ART initiation and virologic suppression
among newly treatment-eligible individuals between 2001 and
2009 in the North American AIDS Cohort Collaboration on
Research and Design (NA-ACCORD). To assess changes over
time in this large cohort, we estimated the annual cumulative
incidence of ART initiation and virologic suppression follow-
ing treatment eligibility. We also examined factors associated




The NA-ACCORD is a collaboration of single- and multisite
prospective cohort studies that includes >100 000 HIV-infected
individuals from >100 sites in the United States and Canada,
and is a regional contributor to the International Epidemiolog-
ical Databases to Evaluate AIDS [13–15]. Each participating
cohort submits data regarding enrolled participants’ demo-
graphic characteristics, prescribed medications, laboratory
tests, clinical diagnoses, and vital status, which undergo
quality control before being combined into standardized anal-
ysis files. Human subjects activities of the NA-ACCORD and
each participating cohort are reviewed and approved by their
respective institutional review boards.
Study Population
The study population included ART-naive HIV-infected
adults (age ≥18 years) newly eligible to initiate ART between
2001 and 2009, from 17 NA-ACCORD cohorts. For consisten-
cy, clinical eligibility was based on US Department of Health
and Human Services treatment guidelines during this period
(ie, an incident AIDS-defining illness [ADI] or a recorded
CD4+ count of <350 cells/µL) [16, 17]. Inclusion criteria were
a known state or province of residence, at least 2 CD4+ counts
in the study period (to ensure adequate follow-up), no prior
CD4+ counts <350 cells/µL or documented ADIs, and no doc-
umented history of ART use.
Outcomes of Interest
The outcomes of interest were time to ART initiation and
time to virologic suppression, using date of ART eligibility (ie,
the first date that an incident ADI or a CD4+ count <350
cells/µL was recorded) as the time origin. Time to ART initia-
tion was defined as the duration between the date of eligibility
and the date ART was started. We used a standard definition
for ART consistent with US guidelines [18]. On the basis of
previous work using a 6-month window to capture successful
initiation of treatment, [19] we censored time to ART initia-
tion at 6 months after eligibility, focusing on timely initiation.
Virologic suppression was defined as any HIV type 1 viral
load (VL) measurement ≤500 copies/mL within 1 year. This
threshold was chosen to account for differences in detection
limits of commercial assays over the study period [20, 21]. We
censored suppression at 1 year after eligibility to focus on
more timely virologic control. Seven percent of subjects did
not have a second VL available by 1 year and were excluded
from further analysis. A secondary outcome was time to viro-
logic suppression, limited to those initiating ART within 6
months of eligibility. For this outcome, we used the date of
ART initiation as the time origin instead of the date of ART
eligibility.
Variables of Interest
Individual-level variables of interest, assessed at ART eligibili-
ty, included age; race/ethnicity; sex; transmission risk (ie, male
sex with men, history of injection drug use [IDU], or other
risk); CD4+ count; VL; calendar year; jurisdiction of residence
(ie, state or province); and psychosocial barriers to ART initia-
tion, including documented histories of non–injection drug
abuse, alcohol abuse, and mental illness. These barriers were
dichotomized based on the presence of more specific diagnos-
es of drug or alcohol abuse/dependence or mental disorders as
derived from electronic medical records and medical record
reviews, and the variables were summed to form a single
ordinal variable. State of residence was not available from 3
US cohorts, and for these the state of the clinic site was used
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as a proxy. To assess potential misclassification due to this de-
cision, we calculated the percentage of individuals living
outside the state of the clinic site from the remaining US clin-
ical cohorts; only 1% lived outside the state of the clinic site.
To account for potential differences in ART initiation influ-
enced by characteristics of the cohorts or clinics themselves,
we used information regarding employment (eg, unemployed,
disabled, working) and insurance status (eg, uninsured, public,
private) collected by a standardized questionnaire adminis-
tered to all US NA-ACCORD clinical cohorts on their study
populations, categorizing each as follows: higher socioeconom-
ic status US clinical cohort, lower socioeconomic US clinical
cohort, US interval cohort, and Canadian cohort. Interval
cohorts differ from clinical cohorts in both timing and data
collection; individuals are followed at specified intervals (eg,
every 6 months) that are unrelated to healthcare visits, and
data are collected according to defined protocols [22]. We also
included variables representing mechanisms undertaken by in-
dividual clinics to assist patients in gaining access to ART,
such as AIDS Drug Assistance Program (ADAP) enrollment,
and distinguished between those performed by clinic staff and
those requiring referral to entities outside the clinic. For
cohorts not surveyed, we used the median of the answers from
participating cohorts.
Statistical Methods
For each calendar year, we estimated the cumulative incidence
of ART initiation (at 6 months of eligibility) and virologic
suppression (at 1 year of eligibility; and among ART initiators,
at 1 year of ART initiation), adjusting for the aforementioned
covariates. We used a published method that determines the
cumulative incidence for a given exposure (eg, calendar year)
by averaging the individual predicted survival curves of people
with that exposure, based on a Cox model stratified by year
[23]. For time to virologic suppression, we excluded the small
number of individuals who already had a VL <500 copies/mL
at eligibility.
We constructed multivariable Cox regression models to de-
termine hazard ratios for factors associated with time to ART
initiation and time to virologic suppression. We explored po-
tential interactions between these factors and calendar time
(ie, 2001–2005 and 2006–2009) in subgroup analyses by time
period, based on observed time trends. Because not all cohorts
could provide information on each of the psychosocial barriers
examined, we performed sensitivity analysis among the 11
cohorts contributing data on all 3 (n = 9370). To account for
potential selection bias in the analysis of virologic suppression
among those who initiated treatment, we performed a sensitiv-
ity analysis using inverse probability of selection weighting as
an alternative to simply limiting the analysis to ART initiators
(Supplementary Appendix). We also replaced time-to-event
outcomes with dichotomous outcomes as a further sensitivity
analysis. Overall inferences did not change using these alter-
nate approaches.
We tested for geographic heterogeneity in each outcome
using likelihood ratio testing, with jurisdiction of residence
modeled as a random effect. Because representativeness of es-
timates in NA-ACCORD to the general HIV-infected popula-
tion may vary within each jurisdiction, we limited estimates to
those with ≥100 eligible individuals and ≥1000 participants in
the overall NA-ACCORD, and reported estimates by geo-
graphic region instead of the jurisdictions themselves.
Analyses were conducted using SAS software version 9.2
and the R package version 2.15.0. A P value < .05 guided stat-
istical interpretation.
RESULTS
From 115 882 living HIV-infected individuals in NA-
ACCORD between 2001 and 2009, 10 692 were ART-naive
and became newly eligible for ART initiation during the study
period. There were 9186 (86%) participants eligible for analy-
ses of virologic suppression because they were not suppressed
at eligibility and had at least 1 VL recorded within 1 year. Par-
ticipant characteristics are listed in Table 1. Thirty-four
percent were eligible for ART because of a CD4+ count < 200
cells/µL, and an additional 63% had a CD4+ count between
200 cells/µL and 350 cells/µL. Only 3.6% were eligible for
ART based solely on an incident ADI. Among the partici-
pants, 0.3% had both a CD4+ count < 350 cells/µL and an inci-
dent ADI.
The study population comprised 9619 individuals from 33
US states (plus the District of Columbia) and 1073 from 5
Canadian provinces. Fourteen states and 3 provinces had suffi-
cient representation to estimate cumulative incidence at the ju-
risdictional level (Supplementary Appendix Table 1). The 3
most highly represented jurisdictions were California (19%),
New York (18%), and Texas (11%).
Trends in ART Initiation and Virologic Suppression, 2001–2009
Figure 1 shows time trends in ART initiation and virologic
suppression. The adjusted 6-month cumulative incidence of
ART initiation was 57% overall, increasing from 51% in 2001
to 72% in 2009. The adjusted cumulative incidence of virolog-
ic suppression after 1 year of ART eligibility was 62%, increas-
ing from 55% in 2001 to 81% in 2009. Among ART initiators,
the cumulative incidence of virologic suppression after 1 year
was 87%, increasing from 84% in 2001 to 93% in 2009. All
trends were statistically significant (Ptrend < .001), and general-
ly persisted within individual cohorts (data not shown).
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Factors Associated With ART Initiation and Virologic
Suppression
Table 2 shows factors associated with ART initiation and viro-
logic suppression. Increasing age was associated with both
more timely ART initiation and virologic suppression, among
both the full study population (Ptrend < .001) and the subset
who initiated ART (Ptrend = .001). Regarding race/ethnicity,
those in the “other” category (comprising mostly Native Amer-
icans and Canadian aboriginals) were less likely to have timely
ART initiation than those of white race (adjusted hazard ratio
[HR], 0.84 [95% confidence interval {CI}, .72–.98]), but this
association disappeared when examining virologic suppression.
Compared to those with a CD4+ count 200–349 cells/µL,
those with a CD4+ count <200 cells/µL were more likely to
have timely ART initiation (HR, 2.29 [95% CI, 2.16–2.42]) and
virologic control (HR, 1.75 [95% CI, 1.64–1.85]) after eligibili-
ty. However, among ART initiators, those with a CD4+ count
<200 cells/µL were no more or less likely to become suppressed
(HR, 0.99 [95% CI, .93–1.05]). Individuals clinically eligible
for treatment solely due to an ADI were less likely to initiate
ART (HR, 0.66 [95% CI, .55–.79]) or achieve suppression (HR,
0.85 [95% CI, .71–1.01]) than those with a CD4+ count 200–
349 cells/µL, but once initiating ART, they also reached similar
suppression (HR, 0.93 [95% CI, .76–1.15]).
Figure 1. Trends in antiretroviral therapy (ART) initiation and virologic
suppression among newly treatment-eligible individuals in North
America, NA-ACCORD, 2001–2009. Solid circles: ART initiation 6 months
after eligibility; hollow squares: virologic suppression 1 year after eligibil-
ity; solid squares: virologic suppression 1 year after ART initiation. Error
bars represent 95% confidence intervals. Estimates were adjusted for
age; race/ethnicity; sex; transmission risk; documented history of non–
injection drug abuse, alcohol abuse, and mental illness; CD4+ count and
viral load at eligibility; jurisdiction of residence; type of cohort; and
clinic-specific mechanisms undertaken to assist with access to ART. Un-
adjusted trends (not shown) were similar.
Table 1. Characteristics of Newly Treatment-Eligible HIV-Infected
Individuals, North American AIDS Cohort Collaboration on Re-
search and Design, 2001–2009 (N = 10 692)
Characteristic No. %










Hispanic, any race 1804 17
White 3505 33
Asian/Pacific Islander 159 1.5
Other race/ethnicitya 810 8
Sex and transmission risk
Men who have sex with men 4586 43
Male injection drug user 1151 11
Male, other risk 2125 20
Female injection drug user 464 4
Female, other risk 2366 22
Antiretroviral therapy eligibility criteria
CD4+ count 0–199 cells/µL 3631 34
CD4+ count 200–349 cells/µL 6679 62
Incident AIDS-defining illness 382 4
Viral load at eligibility
Undetectable 774 7
501–9999 copies/mL 1677 16
10 000–99 999 copies/mL 4210 39
≥100 000 copies/mL 2837 27
Missing 1194 11
Documented history of psychosocial barriersb
Alcohol abuse 684 7
Non–injection drug abuse 1303 14
Mental illness 2315 22





Calendar year of eligibility
2001–2005 6035 56
2006–2009 4657 44
a Includes Native Americans, Aboriginal Canadians, and persons of other or
unknown race/ethnicity.
b Among participants with data available, 9865, 9515, and 10 648 had data on
alcohol abuse, non–injection drug abuse, and mental illness, respectively.
c Includes a documented history of alcohol abuse, non–injection drug abuse,
and mental illness.
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A history of IDU was associated with less timely ART initi-
ation and virologic suppression, particularly in female users,
but after taking into account ART initiation, the association
with virologic suppression was diminished (Table 2). We
identified a significant dose–response effect on the basis of an
increasing number of psychosocial barriers (including history
of non–injection drug use, alcohol abuse, and mental illness)
when assessing the hazard of ART initiation (HR decreased
Table 2. Factors Associated With Antiretroviral Therapy Initiation and Virologic Suppression Among Newly Treatment-Eligible
HIV-Infected Individuals (CD4+ Count <350 Cells/µL or AIDS-Defining Illness), 2001–2009
ART Initiation (at 6 mo
of Eligibility)
Viral Load Suppression
(at 1 y of Eligibility)a
Viral Load Suppression








Total 10 692 9186 5329
Age at eligibility
18–29 1848 Ref. 1639 Ref. 910 Ref.
30–39 3434 1.10 (1.02, 1.19) 2987 1.06 (.97, 1.14) 1728 1.08 (.99, 1.19)
40–49 3618 1.14 (1.06, 1.24) 3056 1.11 (1.02, 1.21) 1777 1.11 (1.01, 1.21)
50–59 1460 1.23 (1.12, 1.36) 1236 1.28 (1.16, 1.42) 750 1.24 (1.11, 1.38)
≥60 332 1.13 (.97, 1.33) 268 1.29 (1.10, 1.52) 164 1.12 (.94, 1.34)
Race/ethnicity
White 3505 Ref. 3074 Ref. 1764 Ref.
Asian/Pacific Islander 159 1.18 (.95, 1.47) 140 1.17 (.94, 1.46) 74 1.24 (.97, 1.58)
Black 4414 0.93 (.87, 1.00) 3720 0.95 (.88, 1.02) 2139 0.98 (.90, 1.06)
Hispanic (any race) 1804 1.01 (.93, 1.10) 1529 1.04 (.96, 1.14) 944 0.99 (.90, 1.09)
Other race/ethnicityc 810 0.84 (.72, 0.98) 723 0.99 (.85, 1.15) 408 1.01 (.85, 1.19)
Sex and transmission risk
Men who have sex with men 4586 Ref. 4036 Ref. 2411 Ref.
Female injection drug user 464 0.64 (.54, .75) 365 0.73 (.62, .86) 135 0.85 (.69, 1.04)
Female, other risk 2366 0.87 (.81, .94) 2028 0.99 (.92, 1.06) 1139 0.99 (.91, 1.08)
Male injection drug user 1151 0.81 (.74, .90) 924 0.80 (.73, .89) 462 0.85 (.76, .96)
Male, other risk 2125 1.00 (.93, 1.08) 1833 0.94 (.87, 1.02) 1182 0.91 (.84, .99)
ART eligibility criteria
CD4+ count 0–199 cells/µL 3631 2.29 (2.16, 2.42) 3257 1.75 (1.64, 1.85) 2597 0.99 (.93, 1.05)
CD4+ count 200–349 cells/µL 6679 Ref. 5641 Ref. 2623 Ref.
Incident AIDS-defining illness 382 0.66 (.55, .79) 288 0.85 (.71, 1.01) 109 0.93 (.76, 1.15)
Viral load at eligibility
Undetectable 774 Ref. N/A N/A N/A N/A
501–9999 copies/mL 1677 0.51 (.45, .58) 1539 Ref. 580 Ref.
10 000–99 999 copies/mL 4210 0.79 (.71, .88) 3888 1.24 (1.14, 1.35) 2130 0.77 (.70, .85)
≥100 000 copies/mL 2837 1.04 (.94, 1.16) 2675 1.33 (1.21, 1.45) 2002 0.58 (.52, .64)
Missing 1194 0.69 (.61, .78) 1084 1.35 (1.21, 1.50) 617 0.65 (.57, .74)
No. of psychosocial barriersd
0 7649 Ref. 6573 Ref. 4042 Ref.
1 2033 0.83 (.77, .89) 1757 0.89 (.83, .96) 916 0.99 (.91, 1.07)
2 757 0.70 (.62, .79) 642 0.84 (.75, .94) 289 1.02 (.90, 1.17)
3 253 0.58 (.47, .72) 214 0.66 (.54, .82) 82 0.85 (.66, 1.08)
Calendar year of eligibility 1.05 (1.04, 1.06) 1.07 (1.06, 1.09) 1.03 (1.02, 1.04)
Cox regression, adjusted for all other factors, plus state or province of residence, type of cohort.
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; HIV, human immunodeficiency virus; HR, hazard ratio; N/A, not applicable.
a Excludes those with undetectable viral load at eligibility and those with no viral load within 1 year.
b Also excludes those who did not initiate ART within 6 months.
c Includes Native Americans, Aboriginal Canadians, and persons of other or unknown race/ethnicity.
d Includes a documented history of alcohol abuse, non–injection drug abuse, and mental illness.
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from 0.83 for 1 barrier to 0.58 for 3 barriers, Ptrend < .001) and
suppression (HR decreased from 0.89 to 0.66, Ptrend < .001).
However, limiting the analysis to those who initiated ART
mitigated this association (Ptrend = .53).
Consistent with the aforementioned time trends, there was
a statistically significant increase in ART initiation and viro-
logic suppression with each successive calendar year: 5% and
7% per year, respectively. We explored interactions between all
factors and calendar period (2001–2005, and 2006–2009), but
did not observe any substantial differences in effect estimates
for these factors except for calendar year itself (ie, no annual
change between 2001–2005 for ART initiation [Ptrend = .11],
but a significant increase between 2006–2009 [Ptrend < .001]).
Estimation of Treatment Outcome Rates, by Jurisdiction of
Residence
Among the 14 states and 3 provinces examined, the cumula-
tive incidence of ART initiation after 6 months ranged from
35% to 94% after adjusting for individual- and cohort-level
characteristics (Figure 2A), a 2.7-fold relative difference. We
found a statistically significant effect of jurisdiction of resi-
dence on ART initiation (P < .001), suggesting heterogeneity
exceeding what would be expected by chance.
The adjusted 1-year virologic suppression incidence by ju-
risdiction ranged from 45% to 78% (Figure 2B), with a simi-
larly significant, though smaller, jurisdiction effect (P < .001).
The effect remained statistically significant (P < .001) among
those who initiated ART (Figure 2C). Among states and prov-
inces, the cumulative incidence of ART initiation was only
weakly correlated with virologic suppression (r = 0.14).
DISCUSSION
In this heterogeneous population of HIV-infected individuals
newly eligible to begin ART, we documented between 2001
and 2009 a substantial improvement in timely ART initiation
and resulting virologic suppression, with sustained increases
since 2006. Several temporal changes occurred during this
period, including the use of better tolerated and more conve-
nient formulations, [4] and increasing evidence that starting
therapy earlier results in better outcomes [19, 24–26]. Docu-
menting treatment patterns in this large subset of the North
American HIV-infected population is important as newer in-
terventions are developed to further improve clinical outcomes,
both at the individual level (eg, newer formulations) and at the
Figure 2. Adjusted cumulative incidence of antiretroviral therapy (ART) initiation and virologic suppression, by jurisdiction, 2001–2009. A, ART initia-
tion, through 6 months after eligibility. B, Virologic suppression, through 1 year after eligibility. C, Virologic suppression among ART initiators, through 1
year after initiation. Estimates were adjusted for age; race/ethnicity; sex; transmission risk; documented history of non–injection drug abuse, alcohol
abuse, and mental illness; CD4+ count and viral load at eligibility; calendar year; type of cohort; and clinic-specific mechanisms undertaken to assist
with access to ART. Colors used to identify geographic regions: blue = Northeast United States; green = Western United States; gray = Canada; orange =
Midwest United States; red = Southern United States. Abbreviations: ART, antiretroviral therapy; VL, viral load.
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population level (eg, “test and treat” strategies). As US guide-
lines now recommend starting ART regardless of CD4+ cell
count, [9] it will be even more important to understand tem-
poral trends in ART initiation and resulting clinical outcomes.
We confirmed previously noted barriers to timely initiation
of ART, such as younger age and higher CD4+ counts [27, 28].
Less timely ART initiation among those solely eligible due to
an incident ADI may have been a consequence of concerns
about immune reconstitution inflammatory syndrome, as data
supporting the safety of initiating ART in such individuals
were not available until recently, [29] or of physicians wanting
patients to demonstrate adherence to opportunistic infection
treatment before prescribing ART [30].
We also identified potential barriers to ART initiation that,
once overcome, may play less of a role in achieving virologic
suppression, which is an immediate goal of ART. Persons with
a history of IDU were less likely to initiate ART or achieve
virologic suppression compared to other risk groups, but these
differences were moderated when suppression was considered
among injection drug users who initiated ART. The effects of
other factors often considered stumbling blocks for patients—
such as a history of mental illness, abuse of other drugs and
alcohol, and the co-occurrence of these [31]—were also miti-
gated when examining their impact on achieving virologic
suppression. These findings are consistent with some studies
that have found that if people have adequate support systems
when they initiate treatment, they can greatly improve their
chances of virologic success [32–34]. Additional studies that
account for duration, severity, and specific diagnoses of
mental illness and substance use are warranted, to better un-
derstand the nuances of their influences on treatment goals.
After we controlled for individual-level factors, disparities
in the timely initiation of therapy by state or province of resi-
dence remained, suggesting that system-level factors likely
contribute to differential ART access. Disparities by state or
province are relevant because there may be policy-related
factors that could be modified to reduce these differences. For
example, an estimated two-thirds of HIV-infected Americans
obtain ART through public programs like Medicaid and the
Ryan White Part B ADAP, [35] where state-specific differences
in funding and eligibility may play a role in observed dispari-
ties [36]. Other recent studies have identified geographic dis-
parities in HIV-related outcomes in the United States [37, 38]
and even in Canada, despite universal healthcare [39]. We are
conducting further studies in NA-ACCORD to assess how dif-
ferences in US state-specific ADAP benefits may factor into
geographic disparities.
Our analysis has several limitations. First, we cannot deter-
mine the extent to which psychosocial barriers delay treat-
ment, either due to a patient’s inability to remain engaged in
care or a provider being less likely to initiate treatment in
patients with disrupted lives [40]. However, our findings
suggest that once individuals do initiate ART, many achieve
virologic suppression despite these barriers. Furthermore, as-
sessment of psychosocial factors was broad in that we did not
distinguish between recent and past history or level of severity,
which may influence the timeliness of treatment initiation and
positive outcomes in different ways. Other potential psychoso-
cial or structural barriers that we did not have information on
include lack of social support, perceived stigma, incarceration,
or unstable housing [41–45] In addition, 1 cohort could not
supply data on mental illness, and 5 did not supply data on
alcohol abuse or non–injection drug abuse. Excluding these
cohorts did not change our findings appreciably (data not
shown), but more complete measurement of these factors will
be valuable in future studies.
Although treatment guidelines aim for successful initiation
of ART and virologic suppression, our study cannot distin-
guish nonuse of ART owing to barriers to treatment vs by
choice, and similarly, virologic failure due to nonadherence
versus metabolic effects. Nonetheless, our analysis adjusts for
many patient- and system-level factors, including mechanisms
that clinics have to assist patients in obtaining medications.
Our jurisdiction-level inferences may not be generalizable
to all HIV-infected persons living in a particular state or prov-
ince, because of the variable extent to which patients attending
individual clinics represent the underlying HIV population.
Therefore, we did not rank states and provinces in terms of
treatment outcomes. However, NA-ACCORD is the largest
longitudinal cohort of HIV-infected individuals with detailed
histories in North America, and its size and diversity play a
major role in being able to monitor the larger population [18].
We followed people through 6 months of eligibility to assess
“timely” ART initiation. However, other HIV-care quality mea-
sures are being developed as performance standards, such as
being prescribed potent ART within a 1-year period [46]. Other
relevant outcomes that could be examined include longer-term
virologic control and retention in care, both of which are im-
portant to fully realize the benefits of ART [47, 48].
The importance of timely ART initiation is now well estab-
lished [9]. Unfortunately many barriers, both at the individual
level and systemwide, complicate access to and successful use
of treatment for people with HIV infection, even in resource-
rich countries. Continued monitoring will be crucial in ad-
dressing these disparities, including those related to geogra-
phy, especially as HIV testing practices change, and, in the
United States, as the Affordable Care Act is implemented [49].
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Boswell, Chris Grasso, and Ken Mayer. HAART Observational Medical
Evaluation and Research: Robert S. Hogg, Richard Harrigan, Julio Monta-
ner, and Angela Cescon. HIV Outpatient Study: John T. Brooks and Kate
Buchacz. HIV Research Network: Kelly A. Gebo. Johns Hopkins HIV
Clinical Cohort: Richard D. Moore. John T. Carey Special Immunology
Unit Patient Care and Research Database, Case Western Reserve Universi-
ty: Benigno Rodriguez. Kaiser Permanente Mid-Atlantic States: Michael
A. Horberg. Kaiser Permanente Northern California: Michael A. Horberg
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Robert F. Hunter-Mellado and Angel M. Mayor. Southern Alberta Clinic
Cohort: M. John Gill. Studies of the Consequences of the Protease Inhibi-
tor Era: Steven G. Deeks and Jeffrey N. Martin. University of Alabama at
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Cohort: Joseph J. Eron and Sonia Napravnik. University of Washington
HIV Cohort: Mari M. Kitahata and Heidi M. Crane. Veterans Aging
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bilt-Meharry Centers for AIDS Research Cohort: Timothy R. Sterling,
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M. Freeman. NA-ACCORD Administrative Core: Richard D. Moore,
Aimee M. Freeman, Carol Lent and Aaron Platt. NA-ACCORD Data
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